Business
Preliminary results for the year ended 31 Dec 2025
Oxford Biomedica PLC reported strong preliminary results for the year ended 31 December 2025, achieving revenue growth of 33% to £170.9 million and reporting an Operating EBITDA profit of £8.1 million, a significant improvement from the previous year's loss. This profitability was bolstered by a one-off gain from the acquisition of a commercial-scale viral vector manufacturing facility in Durham, North Carolina. The company also saw its revenue backlog increase by approximately 36% to £204 million and the contracted value of orders rise by 20% to £224 million, indicating robust commercial momentum and strong future revenue visibility. Looking ahead, Oxford Biomedica provided financial guidance for FY 2026, expecting revenues between £220-240 million and an Operating EBITDA margin of around 10%. Disclaimer*
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n\n \nPreliminary results for the year ended 31 December 2025\n \nA year of strategic execution, strong revenue growth and positive Operating EBITDA\n \n· Strong 2025 financial performance; revenues at upper end of guidance, with full year Operating EBITDA profitability achieved:\n- Revenue growth of 33% to £170.9 million (CC) (FY 2024: £128.8 million)\n- Operating EBITDA profit of £8.1 million (CC) (FY2024: £(15.3) million), driven by revenue growth and increasing focus on operating costs, and including one-off gain from the acquisition of the Durham, North Carolina (NC) facility.\n- Underlying Operating EBITDA CC of £3.3 million, excluding the impact of the Durham, NC facility (the gain, acquisition, integration and site costs).\n· Revenue backlog up c.36% to c.£204 million, a strong indicator of future revenues and continued growth through 2026 and beyond.\n· Contracted value of orders up c.20% YoY to £224 million reflecting strong commercial momentum.\n· Strategic expansion of global CDMO network with acquisition of FDA-approved commercial-scale viral vector manufacturing facility in Durham, NC.\n· New multi-year Commercial Supply Agreement with Bristol Myers Squibb (BMS) for the manufacture and supply of lentiviral vectors for BMS' CAR-T programmes (signed post-period).\n· Financial guidance: FY 2026 revenues of £220 - 240 million with Operating EBITDA margin c.10%; medium‑term revenue growth of 25 - 30% in FY27 - 28 and EBITDA margins rising to at least 20% in FY 2027, with longer‑term potential approaching c.30% over a five-to-six-year period.\n \nOxford, UK - 26 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces preliminary results for the year ended 31 December 2025.\n \nDr. Frank Mathias, Chief Executive Officer of OXB, commented: \"2025 was a year of outstanding execution for OXB as we delivered on our pure-play CDMO strategy. Strong commercial and operational execution resulted in 33% (CC) revenue growth and Operating EBITDA profitability.\n \n\"During the year, we made targeted investments across our global network to expand capacity and increase efficiency, including ...